Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

NCT01394952 · Completed

Last updated 2026-05-28

The REWIND trial tested a weekly incretin medication in adults with type 2 diabetes to see how it affects the risk of heart attacks, strokes, or cardiovascular-related death over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 9,901 people

Who can join Ages 50+ · all sexes

Timeline Started 2011-07 · est. completion 2018-08

Where 300 sites · Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Germany, Hungary, Latvia, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT01394952 ↗

Description as written by the study sponsor.

The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered subcutaneously
Placebo Drug

Administered subcutaneously

Main thing measured	Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)
Sponsor	Eli Lilly and Company
Conditions studied	Cardiovascular Disease, Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01394952 ↗